Nick Abbott's questions to MEI Pharma (MEIP) leadership • Q4 2022
Question
Nick Abbott of Wells Fargo inquired about the timing of data from Kyowa Kirin's Japanese trial of zandelisib, whether MEI has formally proposed revisions to the COASTAL study to the FDA, and the company's interest in a recent publication on intermittent PI3K delta inhibitor dosing in head and neck cancer.
Answer
SVP David Walsey stated that partner Kyowa Kirin has not set a public timeline for its Japanese data but intends to file for full approval. He also confirmed MEI has not yet made a formal proposal to the FDA on COASTAL, as they are conducting complex analysis to ensure a meaningful discussion. CEO Dan Gold added that the company was 'heartened' by the recent head and neck cancer publication, which supports their intermittent dosing strategy, and said to 'stay tuned' for potential exploration in that area.